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a b s t r a c t
The aldol reaction of the endogeneous compounds acetone and methylglyoxal has been studied using
organocatalysis in relation to biologically relevant non-enzymatic reactions. Under preparative condi-
tions, 3-hydroxy-2,5-hexadione, known as Henze’s ketol, is formed in high yield and with enantioselec-
tivities up to 88% ee. Furthermore, Henze’s ketol is also formed under simulated physiological conditions
at micromolar scale, indicating that this reaction might take place in living organisms.
 2009 Elsevier Ltd. All rights reserved.
Organocatalysis has recently proven highly efficient in the
stereoselective synthesis of a large number of a-substituted car-
bonyl compounds.1 The rediscovery of the organocatalytic aldol
reaction in 2000 by List, Lerner and Barbas ushered in a new field
in organic synthesis,2 and research in organocatalysis has since
expanded exponentially. Inspired by the aldolase enzymes, the
organocatalytic aldol reaction employs aminocatalysis for the acti-
vation of carbonyl compounds (aldol donors) by the formation of
transient enamine species. The utility of the stereoselective organ-
ocatalytic aldol reaction has also been demonstrated in a number
of total syntheses3 and the mechanism has been thoroughly stud-
ied by computational methods.4
Acknowledging that organocatalytic aldol reactions have been
reported to proceed in aqueous environments, mediated by simple
amino acid derivatives and peptides1,5 led us to believe that these
reactionsmight occur in vivo.6 Intrigued by this possibility, we initi-
ated a study to address the potential role of non-enzymatic organo-
catalytic reactions in human biochemistry. Asmodel substrates, the
endogenous compoundsmethylglyoxal 1 (pyruvaldehyde) and ace-
tone 2were chosen for our initial experiments.
Methylglyoxal 1 is a reactive endogenous a-oxoaldehyde that is
known to modify biomolecules in vivo through non-enzymatic
processes.7 The development of complications in relation to diabe-
tes, as well as the general aging phenomenon, has been linked to
protein modifications by 1. Although the concentration of ‘free’ 1
in vivo is in the high nM or low lM regime, the bulk of 1 is bound
reversibly to nucleophilic groups present in biopolymers and to
reduced glutathione.8 The total amount of 1 in biological systems
may therefore be significant; for example, up to 310 lM of 1 in cul-
tured CHO-cells9 has been measured and even concentrations in
the mM range have been reported in the gingival fluid from peri-
odontitis patients.10
Acetone 2 belongs to the class of ketone bodies that are present
in elevated (millimolar) levels during prolonged starvation or
poorly controlled diabetes.11 To the best of our knowledge, the
organocatalytic aldol reaction between 1 and 2 has not previously
been studied. The product of this reaction, 3-hydroxy-2,5-hexadi-
one 3, also known as Henze’s ketol,12 bears an interesting history.
The chemistry and biochemistry of 3 was extensively studied by
Henze and his colleagues in the 1930s, and they went so far as to
speculate that 3 might represent an undiscovered link between
the metabolism of fatty acids and carbohydrates. This proposal
was later disproved by Krebs,13 and no clear biological role for 3
has since emerged; however, this ketol has recently been identified
in plant extracts.14 In the present work we report the enantioselec-
tive organocatalytic preparation of 3 on a synthetic scale, as well as
its organocatalytic formation under simulated physiological condi-
tions, at levels that may be biologically significant.
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We explored this reaction using a number of catalysts, as shown
in Table 1. (S)-Proline 4 afforded little or no conversion under pre-
parative conditions at 4 C (entries 1–3). Prolinamide 5 proved to
be a more efficient catalyst in terms of both yield and enantioselec-
tivity (entry 4). The dipeptide Pro-Leu 7 gave better enantioselec-
tivity than 5 at a slightly lower yield (entry 6), while amide 8
offered yield and selectivity comparable to that observed for 5
(entry 7). Catalyst 6 was not effective for this reaction (entry 5)
and the proline derivatives 9 and 10 (entries 8 and 9) offered no
obvious advantages compared to catalysts 5, 7 or 8. Thus, 5, 7,
and 8 all showed promise in this reaction, but we chose to focus
our efforts on 5 and 7 due to the closer resemblance of these cata-
lysts to physiological entities.
We settled on using 20 mol % prolinamide 5 or Pro-Leu 7 as our
standard catalyst loading, at a concentration of methylglyoxal 1 of
0.4 M. We note that 7 has limited solubility in all solvents
explored. Indeed, in all reactions run with catalyst 7, the reaction
mixture was an inhomogeneous suspension, so the precise catalyst
loading when applying 7 is unknown.
The results with prolinamide 5 are shown in Table 2 and the
best results with this catalyst were obtained by running the reac-
tion in neat acetone. Interestingly, both polar protic solvents
(H2O and i-PrOH, entries 8 and 9) and the less polar solvents (tol-
uene and CH2Cl2, entries 1 and 2) gave poorer enantioselectivity
than solvents of moderate polarities (MeCN and acetone, entries
3 and 10). The very polar DMSO also gave poor enantioselectivity
(entry 7). In all of our reactions, we used commercially available
1, which is a 40% aqueous solution. Given the poor enantioselectiv-
ity observed in protic solvents, we investigated the effect of drying
agents on reactions run in MeCN. The addition of Na2SO4 had no
effect on the reaction (entry 4), while the addition of MgSO4 did re-
sult in a small increase in enantioselectivity at a modest expense in
yield (entry 5). It is possible that the increase in selectivity
observed in the presence of MgSO4 is the result of a change in
mechanism to one involving chelation control by magnesium ion,
but in any case, the exclusion of bulk water in the reaction mixture
does not have a large effect on the stereoselectivity of the reaction.
Lowering the reaction temperature to 24 C, using neat acetone,
had a small positive effect on both yield and enantioselectivity
(cf. entries 10 and 11).
The results with the dipeptide Pro-Leu 7 are presented in Table
3. With the exception of water (entry 6) this catalyst consistently
delivered good enantioselectivities (73–88% ee) in all solvents
tested. On the other hand, the yields were generally lower than
those observed with prolinamide 5. CH2Cl2 offered excellent
enantioselectivity, but with very poor conversion, probably as a
result of the low solubility of 7 in this solvent. Of the solvents
examined, neat acetone and EtOH emerged as the solvents of
choice for catalyst 7, with acetone giving the highest enantioselec-
tivity (entry 1) and EtOH providing respectable selectivity at a
higher yield (entry 5).
Table 1
Screening of catalysts for organocatalytic formation of Henze’s Ketol 3 from acetone
and methylglyoxala
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O
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0198
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Entry Catalyst Solvent Yield (%) eeb (%)
1 4 Neat <5 nd
2 4 DMSO <10 51
3 4 H2O <5 nd
4 5 Neat 76 65
5 6 Neat <5 33
6c 7 Neat 55 88
7 8 Neat 81 62
8 9 Neat 52 0
9 10 Neat 39 66
a Standard conditions: To a stirred solution of the catalyst (0.05 mmol) in the
specified solvent (375 lL) and acetone (184 lL) (total solvent volume = 559 lL) at
4 C was added 39 lL methylglyoxal solution (40% in H2O). The reaction was stirred
at 4 C for 20 h and purified using FC.
b Determined using chiral stationary phase GC and confirmed using chiral sta-
tionary phase HPLC.
c Reaction time was 68 h.
Table 2
Optimization of conditions for the prolinamide-catalyzed formation of Henze’s Ketol 3a
H3C CH3
O
CH3
O
O
Solvent
Temp.
H3C
O
CH3
OH
O
N
H NH2
O
5
(20 mol %)
2 1 3
H
Entry Solvent Temperature (C) Yield (%) eeb (%)
1 Toluene 4 44 32
2 CH2Cl2 4 49 56
3 CH3CN 4 66 68
4c CH3CN 4 66 68
5d CH3CN 4 52 76
6 DMF 4 nde 68
7 DMSO 4 47 38
8 H2O 4 70 0
9 i-PrOH 4 74 56
10 Neat 4 76 65
11 Neat 24 83 71
a Standard conditions: To a stirred solution of the catalyst (0.05 mmol) in the
specified solvent (375 lL) and acetone (184 lL) (total solvent volume = 559 lL) at
the specified temperature was added 39 lL methylglyoxal solution (40% in H2O).
The reaction was stirred at the specified temperature for 20 h and purified using FC.
b Determined using chiral stationary phase GC and confirmed using chiral sta-
tionary phase HPLC.
c Na2SO4 added as drying agent.
d MgSO4 added as drying agent.
e The DMF was not readily separated from the product by FC and given that this
solvent offered no obvious advantages in enantioselectivity over others, we did not
attempt further purification that would have allowed a yield determination.
Table 3
Optimization of conditions for the Pro-Leu-catalyzed formation of Henze’s Ketol 3a
Entry Solvent Reaction time (h) Yield (%) eeb (%)
1 Neat 68 55 88
2 i-PrOH 21 16 82
3 i-PrOH 72 30 83
4 DMF 21 51 81
5 EtOH 70 77 81
6 H2O 120 27 45
7 CH2Cl2 20 <5 88
8 DMSO 21 49 73
a Standard conditions: To a stirred solution of the catalyst (0.05 mmol) in the
specified solvent (375 lL) and acetone (184 lL) (total solvent volume = 559 lL) at
the specified temperature was added 39 lL methylglyoxal solution (40% in H2O).
The reaction was stirred at 4 C for the specified time period and purified using flash
chromatography.
b Determined using chiral stationary phase GC and confirmed using chiral sta-
tionary phase HPLC.
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We also investigated the amenability of the reaction to scale-
up. We first ran a gram-scale reaction with the fully soluble proli-
namide 5 in neat acetone at 24 C. Using just 10 mol % 5, we
isolated 1.6 g of Henze’s ketol 3 in 93% yield and with 74% ee—both
values even marginally better than our results on the milligram
scale (Table 2, entry 11). On the other hand, scaling-up the reaction
using the largely insoluble Pro-Leu 7was less successful. The gram-
scale reaction using 10 mol % 7 in neat acetone at 4 C afforded 3
with enantioselectivity (87% ee) comparable to that of the milli-
gram-scale reaction (Table 3, entry 1), but at a significantly lower
yield (37%). Thus, catalyst 5 gives the best overall results at the
gram-scale, and the synthesis of 3 with this catalyst represents a
marked improvement over the racemic, two-step literature prepa-
ration of 3 from methylglyoxal 1 and ethyl acetoacetate.
Due to the importance of methylglyoxal 1 and acetone 2 as
endogeneous compounds and since the aldol reaction can indeed
be catalyzed by physiologically relevant amino acids and small
peptides, we turned our attention to the possible biochemical sig-
nificance of the reaction. We began by exploring the reaction of
acetone 2 with methylglyoxal 1 under conditions designed to
approximate those found in vivo (Eq. 1). Using LC–MS/MS to detect
and quantify Henze’s ketol 3 formed with low concentrations of
the reactants, we gradually increased the complexity of the exper-
imental set-up (Table 4). When 375 lM 1 and 12.5 mM 2 were
incubated at 37 C and pH 7.3 for 24 h, micromolar concentrations
of 3 were detected. (S)-Proline 4 (entry 2) was found to accelerate
the aldol reaction, under these buffered conditions, by a factor of
roughly 2.6 over the background reaction (entry 1). Next, we
exchanged 4 for the 25 amino acids present at >3 lM concentra-
tion in human plasma at the levels found in healthy persons (entry
3).15 Although this environment presents a multitude of reversible
and irreversible binding possibilities for 1, the aldol reaction still
proceeds and is even accelerated over the background reaction.
Thiols are known to bind strongly to 1 (KD = 1.4  105);16 how-
ever, the dynamics of this process still permit 1 to dissociate and
undergo the aldol reaction. As shown in entries 4 and 5, physiolog-
ical concentrations of red-glutathione do not retard the reaction,
and even when 0.29 mM human serum albumin (HSA)17 was
included (entry 6), 1.03 lM of Henze’s ketol 3 was observed after
24 h. We have observed that acetoacetate 11, a biological precursor
to acetone during ketosis, turned out to be more reactive than ace-
tone 2 under more demanding conditions in terms of reactant con-
centrations. As shown in entry 7, 3.5% of 1, when present at just
63 lM, was converted into 3 in the presence of 6.3 mM of 11. These
results demonstrate that 1 does react readily with ketones under
conditions that simulate human plasma.
Finally, we explored the preparative-scale reaction of freshly
prepared acetoacetate 11 with methylglyoxal 1 under aqueous
conditions similar to those reported12 in the established two-step
synthesis of Henze’s ketol 3, but with the addition of 30 mol % pro-
linamide 5 (Eq 2). Under these organocatalytic conditions, 3 is
formed in 81% yield, but as a racemate. For comparison, the aldol
reaction of 1 with acetone 2 under the same conditions afforded
3 in 25% yield and with 14% ee. It seems that the aldol reaction
between 1 and 11 under these conditions is so facile that it is
not influenced by the organocatalyst, which is consistent with
our observations of the reactivity of 11 under the simulated phys-
iological conditions (Table 4, entry 7).
O
CO2EtH3C
O
CO2H3C
11
1. Pi buffer + HCl to
adjust pH = 7.8
2. 1, 30 mol% 5, 21 h
H3C
CH3
O
O
OH
3
KOH
H2O
ð2Þ
We have shown that methylglyoxal 1 is an efficient aldol accep-
tor and that preparative organocatalytic reactions can be carried
out with the commercially available solution of 1 and acetone 2
with high yields and enantioselectivities. Furthermore, the aldol
product 3 is also readily formed under simulated in vivo conditions.
Although the rate acceleration here is modest, our results encour-
age further investigations into the role organocatalysis may play
in human biochemistry and how it may impact the turn-over of
methylglyoxal during ketosis. Further studies are aimed at identify-
ing these aldol products in vivo, as well as establishing if the
reactions are enantioselective under conditions found in vivo.
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